Valuation: Virbac

Market Cap 2.62B 2.93B 2.44B 2.22B 4.17B 283B 4.2B 29.32B 11.45B 144B 10.99B 10.75B 463B P/E 2026 *
15.1x
P/E 2027 * 13.6x
Enterprise Value 2.74B 3.06B 2.55B 2.32B 4.37B 296B 4.4B 30.69B 11.99B 151B 11.5B 11.25B 485B EV / Sales 2026 *
1.77x
EV / Sales 2027 * 1.62x
Free-Float
49.03%
Yield 2026 *
0.55%
Yield 2027 * 0.65%
1 day-6.07%
3 months-6.07%
6 months-0.39%
Current year-12.16%
Current year 382.75
Extreme 382.75
413.75
1 year 382.75
Extreme 382.75
436.32
3 years 288
Extreme 288
436.32
5 years 288
Extreme 288
436.32
10 years 131
Extreme 131
436.32
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
-6.07%-.--% - - 2.95B
+3.34%+3.89%+42.49%+110.25% 1,032B
+2.11%-1.74%+37.72%+64.08% 614B
+2.58%+4.66%+17.59%+83.61% 471B
+1.04%-1.25%+63.78%+37.31% 350B
+2.92%+3.12%+24.78%+43.51% 337B
+2.42%+0.05%+14.13%+36.19% 268B
+1.86%-0.81%-4.69%+12.20% 246B
+2.53%-1.91%+39.90%+52.26% 218B
+2.27%-0.92%+26.46%+96.75% 179B
Average +1.28%-3.39%+29.13%+59.57% 412.76B
Weighted average by Cap. +2.34%-3.18%+32.85%+70.42%

Financials

2026 *2027 *
Net sales 1.55B 1.73B 1.44B 1.31B 2.47B 168B 2.49B 17.35B 6.78B 85.19B 6.5B 6.36B 274B 1.64B 1.84B 1.53B 1.39B 2.62B 178B 2.64B 18.43B 7.2B 90.54B 6.91B 6.76B 291B
Net income 174M 195M 162M 147M 278M 18.83B 280M 1.95B 762M 9.58B 731M 715M 30.78B 194M 217M 181M 164M 309M 20.97B 312M 2.17B 849M 10.67B 814M 796M 34.29B
Net Debt 122M 137M 114M 104M 195M 13.25B 197M 1.37B 536M 6.74B 514M 503M 21.66B 44.72M 50.05M 41.72M 37.9M 71.37M 4.84B 71.91M 501M 196M 2.46B 188M 184M 7.92B
Projected Income Statement - Annual - Virbac
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Virbac
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
312.00EUR
Average target price
412.75EUR
Spread / Average Target
+32.29%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Virbac